Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《World Clinical Drugs》 2006-09
Add to Favorite Get Latest Update

Comparison of the Effects of Candesartan Cilexetil and Irbesartan on Mild and Moderate Essential Hypertension

Fu Chun-Jiang, Wang Xu-Kai, Yang Cheng-Ming, Wang Hong-Yong, Shi Wei-Bin, Yan Li-Li (Department of Cardiology, Institute of Surgery Research, Daping Hospital, The Third Military Medical University)  
Objective To evaluate the efficacy and safety of candesartan cilexetil in the treatment of patients with mild- to-moderate essential hypertension. Methods This was a double-blind, double-modelling, randomised, parallel group study. After a placebo run-in period of 2 weeks, 60 patients with essential hypertension were administered candesartan cilexetil 8mg(n=30)or irbesartan 150mg(n=30)once daily for 2 weeks. If the blood pressure was still over standard, the dosages of candesartan cilexetil or irbesartan would be increased to 12mg or 225mg once daily from the 3th week till the end of 4th week. Blood pressure and heart rate were determined, and adverse drug reactions were observed every 2 weeks. Before and after the trial, laboratory tests were performed. Result The systolic blood pressure(SBP) and diastolic blood pressure (DBP) decreased significantly after the treatment for 4 weeks in both groups. The SBP and DBP were decreased by 15.1% and 12.2% in candesartan cilexetil group, and by 12.6% and 9.2% in irbesartan group.There was no significant difference between two groups. There were no serious adverse drug reactions in both groups. Conclusion Candesartan cilexetil can be used in the treatment of patients with mild and moderate essential hypertension effectively and safely.
【Key Words】: candesartan cilexetil irbesartan essential hypertension
【CateGory Index】: R544.1
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
【Citations】
Chinese Journal Full-text Database 1 Hits
1 LIN Yang, BAI Shu Gong, ZHU Xiao ling, YU Zhen qiu, LI Yu, ZHANG Wen, ZHANG Juan, HAN Zhi hong, LIU Wen Xian(Beijing Anzhen Hospital, Affiliated Hospital of Capital University of Medical Sciences, Beijing 100029,China);Clinical study of irbesartan in the treatment of mild and moderate essential hypertension[J];The Chinese Journal of Modern Applied Pharmacy;2003-06
【Co-citations】
Chinese Journal Full-text Database 3 Hits
1 HU Yan,XU Chuan-xin(The First People's Hospital of Jingzhou of Hubei,Jingzhou 434000,China);Meta-analysis of Efficacy and Safety of Valsartan vs. Common Antihypertensive Drugs in the Treatment of Mild to Moderate Essential Hypertension[J];China Pharmacy;2008-02
2 JIANG Dong-bo, MA Xiao-li, CAI Wei-ming(Dept. of Pharmacy, The Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China)WU Tie(Dept. of Pharmacology, Guangdong Medical College, Zhanjiang 524023, China);Content Determination of Main Components and Related Substances in Irbesartan Sustained-release Capsules by RP-HPLC[J];China Pharmacy;2009-04
3 SUN Qi-quan1, LIU Yan2, SHI Jie-hua3, WANG Rong1 (1. Zhejiang Jiangbei Pharmaceutical Co., Ltd., Taizhou, Zhejiang 318017 China;2. Department of Chemistry, Guangxi Teachers Education University, Nanning, Guangxi 530001 China;3. College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, Zhejiang 310032 China);Determination of Irbesartan and Its Related Substances by RP-HPLC[J];Zhejiang Chemical Industry;2006-06
【Secondary Citations】
Chinese Journal Full-text Database 8 Hits
1 Sun Ai - hua Mei Ke - zhi Li Qing (Guang Zhou Red Cross Hospital, GuangDong Guangzhou 510220 China);ONical Observer the Ireat Effect of Irbesartan in Essential Hypertention Patients[J];Chinese Journal of Medicinal Guide;2002-02
2 SUN Xing-CHang HUANG Jie ZHANG Chao-Yang FAN CHao-Met JIA You-Hong LI Yi-SHi (Department of Clinical Pharmacology, Fu Wai Hospital, Chinese Academy of Medical Sciences, Beijing 100037);Effects of Irbesartsn on Heart Rat6 Variability in Patients With Essential Hypertention[J];The Chinese Journal of Clinical Pharmacology;2001-03
3 LIU Shao yan,GONG Jun li(The Department of Cardiology,The Central Hospital of Changchun City,Changchun 130051,Jilin);The clinical observed on the chronil congestive heart failure after Irbesartan and captopril treatment[J];Jilin Medical Journal;2001-06
4 ZHANG Li, MA Ji, LIN Shanyan. Division of Nephrology, Huashan Hospital, Medical Center of Fudan University, Shanghai, 200040;Comparison of irbesartan with fosinopril effects on renal TGFβ_1 expression in diabetic rats[J];Shanghai Medical Journal;2002-01
5 CAI Si-yu 1, ZHANG Xue-hua 1, HU Xiao-sheng 2, L*B Xing-guang 1, SHAN Jiang 1 (1. Department of Cardiology, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou ZHEJIANG 310009, China; 2. Department of Cardiology, First A;Irbesartan in treatment of mild to moderate essential hypertension[J];Chinese Journal of New Drugs and Clinical Remedies;2002-05
6 LIU Hong jun 1, CHANG Ling 1, WANG Hong yi 2, WANG Wei 1, SUN Wei na 1 (1. Hospital of Northern Jiaotong University, BEIJING 100044,China; 2. Department of Cardiology, Affiliated People's Hospital of Beijing University, BEIJING 100034,China);Irbesartan in treating mild to moderate essential hypertension[J];Chinese Journal of New Drugs and Clinical Remedies;2002-07
7 Tan Jian-Qiang (Department of Cardidogy, First People's Hospital of Kaiping, Kaiping 529300);Clinical investigation of irbesartan in treatment of chronic congestive heart failure[J];Chinese Journal of Clinical Pharmacology and Therapeutics;2002-02
8 Pan Qichao ( Cancer Institute,Sun Yatsen University of Medical Sciences,Guangzhou 510060);NEW ANTIHYPERTENSIVE DRUG ANGIOTENSIN Ⅱ RECEPTOR ANTAGONIST[J];CHINESE NEW DRUGS JOURNAL;1999-09
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved